APA (7th ed.) Citation

B, S., T, Y., AB, E., M, K., Y, S., M, T., . . . U, A. (2023). Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Clinical and translational science, 16(8), 1445. https://doi.org/10.1111/cts.13544

Chicago Style (17th ed.) Citation

B, Sangro, et al. "Exposure-response Analysis for Nivolumab Plus Ipilimumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040)." Clinical and Translational Science 16, no. 8 (2023): 1445. https://doi.org/10.1111/cts.13544.

MLA (9th ed.) Citation

B, Sangro, et al. "Exposure-response Analysis for Nivolumab Plus Ipilimumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040)." Clinical and Translational Science, vol. 16, no. 8, 2023, p. 1445, https://doi.org/10.1111/cts.13544.